Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who wrote (10204)	9/9/2009 2:16:41 PM
From: IRWIN JAMES FRANKEL	2 Recommendations Read Replies (2) of 10345

>>And the number of AERs prevented by using Tysabri instead of copaxone or interferons FAR outweighs the risks for patients with active MS (in my opinion.) I think Harold makes a couple of good points. 1 in 1,200 may overstate the risk. That formulation of the risk totally ignores the risk of untreated or inadequately treated MS. While my wife was on Copaxone, she had two very bad exacerbations. They were scary - I will spare you the details. She was hospitalized and bed ridden. She has now been on Tysabri for about 21 months. So far not one exacerbation that we can identify and she has recovered many of her deficits - but not all. I am grateful for the many years that Copaxone helped slow her disease course - and I do believe that happened. But Tysabri is indeed a significant advance even with the PML risk counted. I do hope that ACOR will get Fampridine-SR approved. I think they will. In fact, my wife's doctor must too - since she is about to start my wife on the drug through a compounding pharmacy. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next